Navigation Links
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
Date:5/13/2009

BOSTON, May 13 /PRNewswire/ -- Follica Inc., a privately held developer of novel therapies for androgenetic alopecia and other hair follicle and skin disorders, today announced that William D. Ju, M.D. has been appointed as president and chief executive officer. Dr. Ju succeeds Daphne Zohar, managing partner of PureTech Ventures, who was the Founding CEO of Follica. Dr. Ju will join existing Board members including Ms. Zohar, Mr. G. Kirk Raab, former CEO, Genentech, president and COO, Abbott and current chairman, Follica, Protalex, and Transcept, Dr. Kevin Bitterman, principal at Polaris Venture Partners, and Mr. Chris Ehrlich, general partner at InterWest Partners.

"We are thrilled to welcome Bill Ju as the CEO of Follica. He brings the ideal blend of dermatology and drug development experience, creativity and leadership skills to Follica in this next exciting phase of development," stated Ms. Zohar.

Dr. Ju is a board-certified dermatologist who has 17 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. Prior to joining Follica, he was chief operating officer at PTC Therapeutics, a privately-held biopharmaceutical company. In that position, Dr. Ju played an important role in successfully leading and building the company from a discovery organization into a late-phase clinical and early-stage commercialization company. Since 2003 while he was there, Dr. Ju helped PTC triple in size, complete a $50 million Series E round, and enter into a partnership with Genzyme, the terms of which included a $100 million upfront payment, up to $337 million in milestones, and royalties on sales. Prior to PTC, he was vice president in research and development at Pharmacia Corporation and held executive positions at Merck Research Laboratories in a broad spectrum of product development functions. Dr. Ju served as project leader for SUTENT(R), introduced CANCIDAS(R) into humans, and was p
'/>"/>

SOURCE Follica Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
2. OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific
3. iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development
4. The Arcas Group Appoints Executive Vice President
5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
6. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
7. Nfocus Neuromedical Appoints Robert OHolla to Head Regulatory
8. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
9. Vasogen Appoints Dr. Eldon Smith Chairman
10. DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
11. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... manufacture parts and assemble MOD® units, an innovative medication dispenser produced ... ... February 15, 2009 -- Zeus, Inc., a global leader in the ... new partnership with Avancen MOD Corporation. Avancen produces the MOD ...
... 13 On February 10, 2009, NeoStem, Inc. (NYSE ... NYSE Alternext US (the "Alternext") indicating that the Company ... Alternext Company Guide (the "Guide"), which requires a listed ... November 3, 2008, the Company had announced that it ...
... Feb. 13 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) ... the biopharmaceutical industry, it has maintained its focus ... of sustained profitability. The Company was announcing results ... , In a news release today, William J. ...
Cached Biology Technology:Zeus Partners with Avancen MOD Corp. 2NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 3Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 4
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... MAIncreasing nitrogen runoff from urban and agriculture land-use is ... reducing this pollutant before it endangers delicate downstream ecosystems, ... from the MBL (Marine Biological Laboratory) Ecosystems Center. ... issue of Nature, are based on a major study ...
... returning to beaches will face the reality of "red tide" ... swimming and pose risks to humans and sea life. ... running through their neighborhoods play a critical role in filtering ... new study published in this week,s edition of the journal ...
... Healthy streams play a major role in minimizing the ... delivered downstream. This ecosystem service is valuable; excess nitrogen ... and depleting the water of oxygen. This phenomenon, also ... This week, a team of scientists that included ...
Cached Biology News:Increasing nitrogen pollution overwhelms filtering capability of streams 2From the backyard to the ocean: New study shows streams act as key nitrogen filters 2Small streams mitigate human influence on coastal ecosystems 2
Cytofix Buffer 100 mls...
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Request Info...
Biology Products: